404
Pancreatic Cancer Diagnostic Market Report
Global Pancreatic Cancer Diagnostic Market, Dynamics, and Market Analysis
The pancreatic cancer diagnostic market size is expected to reach USD 3.5 billion in the foreseeable future.
F. Hoffmann-La Roche AG (Switzerland), Myriad Genetics (The U.S), GE Healthcare (The U.S), BD (India), Koninklijke Philips N.V. (Netherlands), Siemens AG (Germany), Abbott Laboratories (The U.S), Hitachi Medical Corporation (Japan), Canon Medical Systems Corporation (Japan), Danaher Corporation (The U.S), Qiagen (Germany), BioMarker Strategies (The U.S) and Asuragen, Inc. (The U.S) are among the key players in the pancreatic cancer diagnostic market.
The pancreatic cancer diagnostic market is expected to witness an impressive growth of 6.7% CAGR in the coming years.
North America accounted for the largest share of pancreatic cancer diagnostic market in 2020.
The imaging segment is expected to remain dominant in the pancreatic cancer diagnostic market in the coming years.
Rising number of people having pancreatic cancer, expand geriatric population, increasing investment in research and development activities to develop advanced diagnostic solutions are the factors driving the growth of pancreatic cancer diagnostic market.
Pancreatic cancer diagnostic distributors, Pancreatic cancer diagnostic suppliers, Pancreatic cancer diagnostic manufacturers, Logistics organizations, Government Bodies are the target audience in the pancreatic cancer diagnostic market.